Video Interview: Nabriva Plans Second Phase III Trial
This article was originally published in Scrip
Having raised just over $90m in an IPO on NASDAQ last year, Nabriva Therapeutics will invest some $80m on two international Phase III trials of its lead pleuromutilin product candidate, lefamulin, to treat community-acquired bacterial pneumonia (CABP). Nabriva CEO Colin Broom tells Mike Ward, Informa Pharma Insights global director of content, the company is poised to start its second trial in 740 patients which he expects to complete in mid-2017.
Register for our free email digests: